Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Revenue (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Revenue for 15 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 3.19% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, down 10.49% year-over-year, with the annual reading at $5.2 million for FY2025, 10.49% down from the prior year.
  • Revenue for Q4 2025 was $1.4 million at Plus Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Revenue was $4.4 million in Q3 2023, with the low at -$247000.0 in Q1 2021.
  • Average Revenue over 5 years is $1.1 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Revenue soared 5927.4% in 2023, then plummeted 66.91% in 2024.
  • Over 5 years, Revenue stood at -$232000.0 in 2021, then soared by 154.74% to $127000.0 in 2022, then soared by 933.86% to $1.3 million in 2023, then increased by 7.54% to $1.4 million in 2024, then fell by 3.19% to $1.4 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $1.4 million, $1.4 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.